Marie D. Ralff

793 total citations
17 papers, 406 citations indexed

About

Marie D. Ralff is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Marie D. Ralff has authored 17 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Immunology and 6 papers in Oncology. Recurrent topics in Marie D. Ralff's work include Cell death mechanisms and regulation (9 papers), interferon and immune responses (4 papers) and Cancer-related Molecular Pathways (4 papers). Marie D. Ralff is often cited by papers focused on Cell death mechanisms and regulation (9 papers), interferon and immune responses (4 papers) and Cancer-related Molecular Pathways (4 papers). Marie D. Ralff collaborates with scholars based in United States, France and United Kingdom. Marie D. Ralff's co-authors include Wafik S. El‐Deiry, David T. Dicker, Jessica Wagner, C. Leah B. Kline, Amriti R. Lulla, Joshua E. Allen, Avital Lev, Varun V. Prabhu, Lanlan Zhou and Philip H. Abbosh and has published in prestigious journals such as Journal of Clinical Investigation, PLoS ONE and Cancer Research.

In The Last Decade

Marie D. Ralff

15 papers receiving 406 citations

Peers

Countries citing papers authored by Marie D. Ralff

Since Specialization

Citations

This map shows the geographic impact of Marie D. Ralff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie D. Ralff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie D. Ralff more than expected).

Fields of papers citing papers by Marie D. Ralff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie D. Ralff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie D. Ralff. The network helps show where Marie D. Ralff may publish in the future.

Co-authorship network of co-authors of Marie D. Ralff

This figure shows the co-authorship network connecting the top 25 collaborators of Marie D. Ralff. A scholar is included among the top collaborators of Marie D. Ralff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie D. Ralff. Marie D. Ralff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Title	Journal	Authors	Indexed citations
1	miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.	PubMed	Amriti R. Lulla, Yan Zhou et al.	2
2	Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo	Cancer Biology & Therapy	Marie D. Ralff, Aakash Jhaveri et al.	11
3	Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo	Cancer Biology & Therapy	Aakash Jhaveri, Lanlan Zhou et al.	11
4	TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic	Oncotarget	Marie D. Ralff, Aakash Jhaveri et al.	17
5	Abstract 262: Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro	Cancer Research	Marie D. Ralff, David T. Dicker et al.	1
6	Abstract 262: Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro		Marie D. Ralff, David T. Dicker et al.	0
7	Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic		Marie D. Ralff, Avital Lev et al.	1
8	Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic	Cancer Research	Marie D. Ralff, Avital Lev et al.	3
9	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer	Molecular Cancer Research	Avital Lev, Amriti R. Lulla et al.	22
10	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment	Journal of Clinical Investigation	Jessica Wagner, C. Leah B. Kline et al.	55
11	Abstract LB-082: ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation	Cancer Research	Marie D. Ralff, Jessica Wagner et al.	0
12	TRAIL pathway targeting therapeutics	Expert Review of Precision Medicine and Drug Development	Marie D. Ralff, Wafik S. El‐Deiry	28
13	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms	Molecular Cancer Therapeutics	Marie D. Ralff, C. Leah B. Kline et al.	38
14	Role of Dopamine Receptors in the Anticancer Activity of ONC201	Neoplasia	C. Leah B. Kline, Marie D. Ralff et al.	94
15	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors	PLoS ONE	Varun V. Prabhu, Amriti R. Lulla et al.	30
16	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212	Cell Cycle	Jessica Wagner, C. Leah B. Kline et al.	56
17	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP	Oncotarget	Avital Lev, Amriti R. Lulla et al.	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact